Diag Capital Management
Latest statistics and disclosures from Diag Capital Management's latest quarterly 13F-HR filing:
- Central Index Key (CIK): 0001687807
Tip: Access up to 7 years of quarterly data
Positions held by Diag Capital Management consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Diag Capital Management
Diag Capital Management holds 40 positions in its portfolio as reported in the December 2018 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Baxter International (BAX) | 6.3 | $5.7M | 86k | 65.82 |
|
|
| Athenex | 6.1 | $5.4M | 429k | 12.69 |
|
|
| Zimmer Holdings (ZBH) | 5.5 | $4.9M | 48k | 103.72 |
|
|
| Abbvie (ABBV) | 5.2 | $4.6M | 50k | 92.19 |
|
|
| Incyte Corporation (INCY) | 5.1 | $4.6M | 72k | 63.59 |
|
|
| Quanterix Ord (QTRX) | 4.6 | $4.1M | 224k | 18.31 |
|
|
| Celgene Corporation | 4.5 | $4.0M | 63k | 64.09 |
|
|
| Amgen (AMGN) | 4.4 | $3.9M | 20k | 194.68 |
|
|
| Foamix Pharmaceuticals | 3.7 | $3.3M | 146k | 22.60 |
|
|
| Medtronic (MDT) | 3.7 | $3.3M | 36k | 90.96 |
|
|
| Quotient | 3.6 | $3.2M | 527k | 6.12 |
|
|
| Pacira Pharmaceuticals conv | 3.6 | $3.2M | 75k | 43.02 |
|
|
| Takeda Pharmaceutical (TAK) | 3.3 | $3.0M | 177k | 16.82 |
|
|
| Abbott Laboratories (ABT) | 3.1 | $2.8M | 39k | 72.33 |
|
|
| Zai Lab (ZLAB) | 3.1 | $2.8M | 120k | 23.22 |
|
|
| Mylan Nv | 3.0 | $2.7M | 99k | 27.40 |
|
|
| Polarityte | 2.8 | $2.5M | 183k | 13.49 |
|
|
| Viewray (VRAYQ) | 2.7 | $2.4M | 397k | 6.07 |
|
|
| Regeneron Pharmaceuticals (REGN) | 2.4 | $2.2M | 5.8k | 373.45 |
|
|
| Teva Pharmaceutical Industries (TEVA) | 2.4 | $2.2M | 140k | 15.42 |
|
|
| Akorn | 2.4 | $2.1M | 634k | 3.39 |
|
|
| Haemonetics Corporation (HAE) | 2.4 | $2.1M | 21k | 100.05 |
|
|
| Argenx Se (ARGX) | 1.8 | $1.6M | 17k | 96.10 |
|
|
| Biohaven Pharmaceutical Holding | 1.6 | $1.4M | 38k | 36.98 |
|
|
| Merit Medical Systems (MMSI) | 1.6 | $1.4M | 25k | 55.79 |
|
|
| Sanofi-Aventis SA (SNY) | 1.5 | $1.3M | 30k | 43.42 |
|
|
| Gw Pharmaceuticals Plc ads | 1.5 | $1.3M | 14k | 97.40 |
|
|
| Livanova Plc Ord (LIVN) | 1.2 | $1.1M | 12k | 91.45 |
|
|
| Molecular Templates | 1.1 | $985k | 244k | 4.04 |
|
|
| Verrica Pharmaceuticals | 1.0 | $937k | 115k | 8.15 |
|
|
| Neurocrine Biosciences (NBIX) | 1.0 | $876k | 12k | 71.42 |
|
|
| Dentsply Sirona (XRAY) | 0.8 | $757k | 20k | 37.20 |
|
|
| Axonics Modulation Technolog (AXNX) | 0.8 | $702k | 47k | 15.10 |
|
|
| Arya Sciences Acquisition Co unit 10/04/2023 | 0.6 | $522k | 51k | 10.34 |
|
|
| Adma Biologics (ADMA) | 0.5 | $435k | 182k | 2.39 |
|
|
| Madrigal Pharmaceuticals (MDGL) | 0.4 | $326k | 2.9k | 112.80 |
|
|
| Arvinas Ord (ARVN) | 0.3 | $311k | 24k | 12.85 |
|
|
| Novavax Inc note 3.750% 2/0 | 0.3 | $286k | 155k | 1.84 |
|
|
| Neos Therapeutics | 0.3 | $278k | 169k | 1.65 |
|
|
| Anaptysbio Inc Common (ANAB) | 0.1 | $95k | 1.5k | 63.63 |
|
Past Filings by Diag Capital Management
SEC 13F filings are viewable for Diag Capital Management going back to 2018
- Diag Capital Management 2018 Q4 filed Feb. 14, 2019